1-Phenylsulfonylmethylcyclohexane carboxylic acid | 274685-76-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Phenylsulfonylmethylcyclohexane carboxylic acid
• 英文别名: 1-Phenylsulfonylmethylcyclohexane-carboxylic acid；1-(benzenesulfonylmethyl)cyclohexane-1-carboxylic acid
• CAS: 274685-76-6
• 化学式: C₁₄H₁₈O₄S
• 分子量: 282.361
• InChiKey: NAHIIYWCQMKEPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Phenylsulfonylmethylcyclohexane carboxylic acid 在 二苯基膦叠氮化物 、 三乙胺 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir®: A change in direction in the search for a second generation HCV NS3 protease inhibitor

  摘要：

  In the search for a second generation HCV protease inhibitor, molecular modeling studies of the X-ray crystal structure of Boceprevir (R) 1 bound to the NS3 protein suggest that expansion into the S4 pocket could provide additional hydrophobic Van der Waals interactions. Effective replacement of the P4 tertbutyl with a cyclohexylmethyl ligand led to inhibitor 2 with improved enzyme and replicon activities. Subsequent modeling and SAR studies led to the pyridine 38 and sulfone analogues 52 and 53 with vastly improved PK parameters in monkeys, forming a new foundation for further exploration. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.063
• 作为产物：
  描述：

  在 Oxone 作用下， 以 甲醇 、 水 为溶剂， 生成 1-Phenylsulfonylmethylcyclohexane carboxylic acid
  参考文献：
  名称：

  The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir®: A change in direction in the search for a second generation HCV NS3 protease inhibitor

  摘要：

  In the search for a second generation HCV protease inhibitor, molecular modeling studies of the X-ray crystal structure of Boceprevir (R) 1 bound to the NS3 protein suggest that expansion into the S4 pocket could provide additional hydrophobic Van der Waals interactions. Effective replacement of the P4 tertbutyl with a cyclohexylmethyl ligand led to inhibitor 2 with improved enzyme and replicon activities. Subsequent modeling and SAR studies led to the pyridine 38 and sulfone analogues 52 and 53 with vastly improved PK parameters in monkeys, forming a new foundation for further exploration. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.063

文献信息

• Cyclic amide derivatives
  申请人：Fujirebio Kabushiki Kaisha

  公开号：US06117870A1

  公开（公告）日：2000-09-12

  A cyclic amide derivative of formula (I): ##STR1## wherein R.sup.1 represents a substituted alkyl group, a substituted alkenyl group, a substituted amino group, a substituted alkoxyl group, a substituted alkylthio group, a substituted carbamoyl group, a substituted sulfonamide group or a substituted amide group; the ring A represents a saturated cyclic alkyl group with 5 to 7 carbon atoms or a hetero-atom-containing saturated heterocyclic group with 3 to 6 carbon atoms; R.sup.2 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group; R.sup.3 represents a hydrogen atom, a group represented by the general formula R.sup.4 O-- or a group represented by the general formula R.sup.5 (R.sup.6)N-- wherein R.sup.4 represents hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group; R.sup.5 and R.sup.6 may be the same or different and each represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group. The cyclic amide derivative of formula (I) have a strong and selective inhibitory action of a cathepsin K and a clinical efficacy when administered orally.

  公式（I）的环酰胺衍生物：##STR1## 其中，R1代表取代的烷基，取代的烯基，取代的氨基，取代的烷氧基，取代的烷硫基，取代的氨基甲酰基，取代的磺酰胺基或取代的酰胺基；环A代表具有5至7个碳原子的饱和环烷基或具有3至6个碳原子的含杂原子的饱和杂环基；R2代表氢原子，取代或未取代的烷基，取代或未取代的芳香族烃基或取代或未取代的杂环基；R3代表氢原子，由一般式R4O-表示的基团或由一般式R5（R6）N-表示的基团，其中，R4代表氢原子，取代或未取代的烷基，取代或未取代的芳香族烃基或取代或未取代的杂环基；R5和R6可以相同也可以不同，且每个代表氢原子，取代或未取代的烷基，取代或未取代的芳香族烃基或取代或未取代的杂环基。公式（I）的环酰胺衍生物具有强大和选择性的卡他普辛K抑制作用，并在口服给药时具有临床疗效。
• Substituted cyclohexyl carboxylic acid compounds
  申请人：SEIKAGAKU CORPORATION

  公开号：EP1616859A1

  公开（公告）日：2006-01-18

  Cyclic carboxylic acid derivatives represented by the general formula (II); wherein R1 is an amide group substituted with substituted or unsubstituted alkyl groups, substituted alkoxy groups, phenoxy group, 1-naphthyloxy group, 2-naphthyloxy group, substituted or unsubtituted alkenyl groups, substituted or unsubstituted amino groups, substituted or unsubstituted aromatic hydrocarbon groups or substituted or unsubstituted heterocyclic groups and A represents a saturated cyclic alkyl with 5 to 7 carbon atoms. The cyclic carboxylic acid derivatives of formula (II) are useful for the synthesis of cyclic amide derivatives useful as cathepsin K inhibitors.

  由通式 (II) 代表的环状羧酸衍生物； 其中 R1 是被取代或未取代的烷基、取代的烷氧基、苯氧基、1-萘氧基、2-萘氧基、取代或未取代的烯基、取代或未取代的氨基、取代或未取代的芳香烃基或取代或未取代的杂环基取代的酰胺基，A 代表具有 5 至 7 个碳原子的饱和环状烷基。 式（II）的环状羧酸衍生物可用于合成作为胰蛋白酶 K 抑制剂的环状酰胺衍生物。
• Hydroxycarboxylic acid derivatives
  申请人：SEIKAGAKU CORPORATION

  公开号：EP1616867A1

  公开（公告）日：2006-01-18

  Hydroxycarboxylic acid derivatives represented by the general formula (V); wherein: R1 represents a substituted C1-C12 alkyl group; a substituted C2-C6 alkenyl group; a substituted amino group; a substituted C1-C6 alkoxy group; a substituted C1-C6 alkylthio group; a substituted carbamoyl group; a substituted sulfonamide group; or a substituted amide group; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group; the ring A represents a saturated cyclic alkyl group with 5 to 7 carbon atoms; The hydroxycarboxylic acid derivatives of formula (V) are useful for the synthesis of cyclic amide derivatives useful as cathepsin K inhibitors.

  通式 (V) 所代表的羟基羧酸衍生物； 其中 R1 代表取代的 C1-C12 烷基；取代的 C2-C6 烯基；取代的氨基；取代的 C1-C6 烷氧基；取代的 C1-C6 烷硫基；取代的氨基甲酰基；取代的磺酰胺基；或取代的酰胺基； R2 代表氢原子、取代或未取代的烷基、取代或未取代的芳烃基或取代或未取代的杂环基； 环 A 代表具有 5 至 7 个碳原子的饱和环状烷基； 式（V）的羟基羧酸衍生物可用于合成可用作 cathepsin K 抑制剂的环酰胺衍生物。
• N-(3-acyl-2-hydroxyalkyl) cycloalkyl amide derivatives
  申请人：SEIKAGAKU CORPORATION

  公开号：EP1619189A1

  公开（公告）日：2006-01-25

  Alcohol derivatives represented by the general formula (IV); wherein: R1 represents a substituted C1-C12 alkyl group; a substituted C2-C6 alkenyl group; a substituted amino group; a substituted C1-C6 alkoxy group; a substituted C1-C6 alkylthio group; a substituted carbamoyl group; a substituted sulfonamide group; or a substituted amide group; the ring A represents a saturated cyclic alkyl group with 5 to 7 carbon atoms; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group; R3 represents a hydrogen atom, a group represented by the general formula R4O- ; or a group represented by the general formula R5(R6)N-wherein R4 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group; R5 and R6 may be the same or different and each represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group, The cyclic carboxylic acid derivatives of formula (IV) are useful for the synthesis of cyclic amide derivatives useful as cathepsin K inhibitors.

  通式 (IV) 所代表的醇衍生物； 其中 R1 代表取代的 C1-C12 烷基；取代的 C2-C6 烯基；取代的氨基；取代的 C1-C6 烷氧基；取代的 C1-C6 烷硫基；取代的氨基甲酰基；取代的磺酰胺基；或取代的酰胺基； 环 A 代表具有 5 至 7 个碳原子的饱和环状烷基； R2 代表氢原子、取代或未取代的烷基、取代或未取代的芳香烃基或取代或未取代的杂环基； R3 代表氢原子、通式 R4O- 所代表的基团；或通式 R5(R6)N- 所代表的基团，其中 R4 代表氢原子、取代或未取代的烷基、取代或未取代的芳烃基团或取代或未取代的杂环基团；R5 和 R6 可以相同或不同，各自代表氢原子、取代或未取代的烷基、取代或未取代的芳烃基团或取代或未取代的杂环基团、 式（IV）的环状羧酸衍生物可用于合成作为胰蛋白酶 K 抑制剂的环状酰胺衍生物。
• Cyclic amide derivatives which inhibit cathepsin K
  申请人：SEIKAGAKU CORPORATION

  公开号：EP1008592B1

  公开（公告）日：2006-02-01